Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

TTY Biopharm Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

TTY Biopharm şirketinin toplam hissedar öz sermayesi NT$6.5B ve toplam borcu NT$2.4B olup, bu da borç-öz sermaye oranını 36.9% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla NT$10.2B ve NT$3.7B dir. TTY Biopharm 'in FAVÖK'ü NT$1.4B faiz karşılama oranı -25 dur. Şirketin NT$2.8B tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

36.9%

Borç/özkaynak oranı

NT$2.40b

Borç

Faiz karşılama oranı	-25x
Nakit	NT$2.85b
Eşitlik	NT$6.51b
Toplam yükümlülükler	NT$3.74b
Toplam varlıklar	NT$10.25b

Son finansal sağlık güncellemeleri

Here's Why TTY Biopharm (GTSM:4105) Can Manage Its Debt Responsibly

Apr 02

TTY Biopharm (GTSM:4105) Has A Pretty Healthy Balance Sheet

Dec 15

Recent updates

Here's Why TTY Biopharm (GTSM:4105) Can Manage Its Debt Responsibly

Apr 02

Is There An Opportunity With TTY Biopharm Company Limited's (GTSM:4105) 43% Undervaluation?

Mar 15

Are Dividend Investors Making A Mistake With TTY Biopharm Company Limited (GTSM:4105)?

Feb 25

TTY Biopharm Company Limited (GTSM:4105) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

Feb 07

TTY Biopharm Company Limited (GTSM:4105) Analysts Just Cut Their EPS Forecasts Substantially

Jan 19

What Type Of Returns Would TTY Biopharm's(GTSM:4105) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Jan 10

TTY Biopharm (GTSM:4105) Has A Pretty Healthy Balance Sheet

Dec 15

How Does TTY Biopharm Company Limited (GTSM:4105) Fare As A Dividend Stock?

Nov 25

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 4105 'nin kısa vadeli varlıkları ( NT$5.5B ) kısa vadeli yükümlülüklerini ( NT$3.0B ) aşıyor.

Uzun Vadeli Yükümlülükler: 4105 şirketinin kısa vadeli varlıkları ( NT$5.5B ) uzun vadeli yükümlülüklerini ( NT$756.1M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 4105 şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: 4105 şirketinin borç/öz sermaye oranı son 5 yılda 18% seviyesinden 36.9% seviyesine yükseldi.

Borç Kapsamı: 4105 'nin borcu işletme nakit akışı ( 45.3% ) tarafından iyi bir şekilde karşılanmaktadır.

Faiz Kapsamı: 4105 ödediğinden daha fazla faiz kazandırıyor, dolayısıyla faiz ödemelerinin karşılanması bir sorun teşkil etmiyor.

TTY Biopharm Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Here's Why TTY Biopharm (GTSM:4105) Can Manage Its Debt Responsibly

TTY Biopharm (GTSM:4105) Has A Pretty Healthy Balance Sheet

Recent updates

Second quarter 2024 earnings released: EPS: NT$1.05 (vs NT$1.24 in 2Q 2023)

TTY Biopharm Company Limited to Report Q2, 2024 Results on Aug 08, 2024

Now 20% undervalued after recent price drop

TTY Biopharm Company Limited Approves Cash Dividend for the Year 2023

Price target decreased by 9.3% to NT$78.00

Now 20% undervalued after recent price drop

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

TTY Biopharm Company Limited to Report Q1, 2024 Results on May 07, 2024

Upcoming dividend of NT$3.50 per share

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Dividend increased to NT$3.50

TTY Biopharm Company Limited Announces Change of CFO and Financial Officer

TTY Biopharm Company Limited, Annual General Meeting, May 30, 2024

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased by 10% to NT$86.00

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS exceeds analyst expectations

Price target increased by 14% to NT$84.50

TTY Biopharm Company Limited Announces Decision Rendered by the Supreme Court for Validity of the Risperidone Development Agreement Between the Company and Center Laboratories, Inc

Now 20% undervalued after recent price drop

Upcoming dividend of NT$3.40 per share at 4.3% yield

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to NT$71.50

Price target increased to NT$79.50

Less than half of directors are independent

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

TTY Biopharm Company Limited Announces Internal Audit Officer Changes, Effective November 7, 2022

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Upcoming dividend of NT$3.00 per share

TTY Biopharm Company Limited Announces Dividend Distribution, Payable on August 15, 2022

TTY Biopharm Company Limited Announces Cash Dividend for the Year 2021

Price target decreased to NT$73.00

Less than half of directors are independent

TTY Biopharm Company Limited Announces the Resignation of Chou,Te-Yu as Member of Remuneration Committee

Price target decreased to NT$73.67

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Consensus forecasts updated

Third quarter 2021 earnings released: EPS NT$1.02 (vs NT$0.90 in 3Q 2020)

Upcoming dividend of NT$4.00 per share

Price target increased to NT$80.00

Consensus EPS estimates fall to NT$2.87

Second quarter 2021 earnings released: EPS NT$0.13 (vs NT$0.75 in 2Q 2020)

Price target increased to NT$80.20

Price target increased to NT$80.20

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS NT$0.82 (vs NT$1.02 in 1Q 2020)

Here's Why TTY Biopharm (GTSM:4105) Can Manage Its Debt Responsibly

Tty Biopharm Company Limited Proposes Dividend for the Period January 1, 2020 to December 31, 2020

Full year 2020 earnings released: EPS NT$3.72 (vs NT$3.62 in FY 2019)

Is There An Opportunity With TTY Biopharm Company Limited's (GTSM:4105) 43% Undervaluation?

PAION AG Enters into License Agreement with TTY Biopharm Company Limited

Are Dividend Investors Making A Mistake With TTY Biopharm Company Limited (GTSM:4105)?

Price target lowered to NT$73.50

TTY Biopharm Company Limited (GTSM:4105) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

TTY Biopharm Company Limited, Annual General Meeting, Jun 09, 2021

New 90-day low: NT$61.40

TTY Biopharm Company Limited (GTSM:4105) Analysts Just Cut Their EPS Forecasts Substantially

New 90-day low: NT$68.10

What Type Of Returns Would TTY Biopharm's(GTSM:4105) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

TTY Biopharm (GTSM:4105) Has A Pretty Healthy Balance Sheet

How Does TTY Biopharm Company Limited (GTSM:4105) Fare As A Dividend Stock?

TTY Biopharm Company Limited Announces Executive Changes, with Effect from January 20, 2021

Revenue and earnings beat expectations

Third quarter 2020 earnings released: EPS NT$0.89

Market bids up stock over the past week

New 90-day high: NT$84.30

Analysts lower revenue estimates to NT$4.14b

New 90-day low: NT$66.20

Price target lowered to NT$79.33

New 90-day low - NT$68.70

First half earnings released

First half earnings released

Finansal Durum Analizi